SGN CD70A

Drug Profile

SGN CD70A

Alternative Names: SGN 70A; SGN-CD70A

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seattle Genetics
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action Alkylating agents; CD70 antigen inhibitors; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Renal cancer

Most Recent Events

  • 27 Oct 2016 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Refractory metastatic disease, Second-line therapy or greater) in USA (IV)
  • 27 Oct 2016 Discontinued - Phase-I for Renal cancer (Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 12 Aug 2014 Phase-I clinical trials in Non-Hodgkin's lymphoma (Refractory metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02216890)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top